Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience

20021,488 citationsJournal Article

Authors

Andrew D. Seidman · Memorial Sloan Kettering Cancer Center

Clifford A. Hudis · Memorial Sloan Kettering Cancer Center

Mary Kathryn Pierri · Memorial Sloan Kettering Cancer Center

Steven Shak · Memorial Sloan Kettering Cancer Center

Virginia Paton · Memorial Sloan Kettering Cancer Center

Mark Ashby · Memorial Sloan Kettering Cancer Center

Maureen Murphy

Abstract

Trastuzumab is associated with an increased risk of CD, which is greatest in patients receiving concurrent anthracyclines. In most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzumab.

Topics & Keywords

Chemotherapy-induced cardiotoxicity and mitigation HER2/EGFR in Cancer Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 20, Issue 5, pp. 1215-1221

DOI: 10.1200/jco.2002.20.5.1215

Field-Weighted Citation Impact: 24.13